CN104350054B - 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 - Google Patents
作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 Download PDFInfo
- Publication number
- CN104350054B CN104350054B CN201380011917.5A CN201380011917A CN104350054B CN 104350054 B CN104350054 B CN 104350054B CN 201380011917 A CN201380011917 A CN 201380011917A CN 104350054 B CN104350054 B CN 104350054B
- Authority
- CN
- China
- Prior art keywords
- isopropyl
- pyrazolo
- triazin
- benzyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC([C@](C)(C(*)N*)N)NC(*)N Chemical compound CC([C@](C)(C(*)N*)N)NC(*)N 0.000 description 17
- LZMATGARSSLFMQ-UHFFFAOYSA-N CC(C)NC(N)=O Chemical compound CC(C)NC(N)=O LZMATGARSSLFMQ-UHFFFAOYSA-N 0.000 description 1
- ODSNLAHWJMQSAD-UHFFFAOYSA-N CC(C)c(cn[n]1c(O)n2)c1nc2S(C)(=O)=O Chemical compound CC(C)c(cn[n]1c(O)n2)c1nc2S(C)(=O)=O ODSNLAHWJMQSAD-UHFFFAOYSA-N 0.000 description 1
- MTGOAOABFUSGKF-UHFFFAOYSA-N CC(C)c(cn[n]1c(O)n2)c1nc2SC Chemical compound CC(C)c(cn[n]1c(O)n2)c1nc2SC MTGOAOABFUSGKF-UHFFFAOYSA-N 0.000 description 1
- WIWOHHCKWSXYFI-YSTIKXIDSA-N CC(C/C=C/[U])c(cn[n]1c(NCc2ccccc2OC(C)=O)n2)c1nc2O[C@H]1CNCCC1 Chemical compound CC(C/C=C/[U])c(cn[n]1c(NCc2ccccc2OC(C)=O)n2)c1nc2O[C@H]1CNCCC1 WIWOHHCKWSXYFI-YSTIKXIDSA-N 0.000 description 1
- DCOXUCLYBHCTQD-UHFFFAOYSA-N CC1=C(N)OC1(CCN)N Chemical compound CC1=C(N)OC1(CCN)N DCOXUCLYBHCTQD-UHFFFAOYSA-N 0.000 description 1
- PTFQJJDAHUWEAF-BZZOAKBMSA-N CCO/C(/C(C)NC(NCc1ccccc1-[n]1nccc1)[n]1ncc(C(C)C)c1C)=N\C Chemical compound CCO/C(/C(C)NC(NCc1ccccc1-[n]1nccc1)[n]1ncc(C(C)C)c1C)=N\C PTFQJJDAHUWEAF-BZZOAKBMSA-N 0.000 description 1
- FJCZWCURAHLMAT-UHFFFAOYSA-N CCOC(c1nc2c(C(C)C)cn[n]2c(NCc(cccc2)c2-[n]2nccc2)n1)=N Chemical compound CCOC(c1nc2c(C(C)C)cn[n]2c(NCc(cccc2)c2-[n]2nccc2)n1)=N FJCZWCURAHLMAT-UHFFFAOYSA-N 0.000 description 1
- YFDBEDSVQOAWSJ-UHFFFAOYSA-N CCOC(c1nc2c(C(C)C)cn[n]2c(NCc(cccc2)c2-[n]2nccc2)n1)=O Chemical compound CCOC(c1nc2c(C(C)C)cn[n]2c(NCc(cccc2)c2-[n]2nccc2)n1)=O YFDBEDSVQOAWSJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157751.4A EP2634190A1 (en) | 2012-03-01 | 2012-03-01 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP12157751.4 | 2012-03-01 | ||
| PCT/EP2013/054224 WO2013128028A1 (en) | 2012-03-01 | 2013-03-01 | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104350054A CN104350054A (zh) | 2015-02-11 |
| CN104350054B true CN104350054B (zh) | 2017-06-13 |
Family
ID=47757629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380011917.5A Active CN104350054B (zh) | 2012-03-01 | 2013-03-01 | 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9567345B2 (https=) |
| EP (2) | EP2634190A1 (https=) |
| JP (1) | JP6182549B2 (https=) |
| KR (1) | KR101821452B1 (https=) |
| CN (1) | CN104350054B (https=) |
| AU (1) | AU2013224848B2 (https=) |
| BR (1) | BR112014021189B1 (https=) |
| CA (1) | CA2865946C (https=) |
| DK (1) | DK2820020T3 (https=) |
| ES (1) | ES2583231T3 (https=) |
| HU (1) | HUE029264T2 (https=) |
| IL (1) | IL234183A (https=) |
| MX (1) | MX347359B (https=) |
| RU (1) | RU2645347C2 (https=) |
| SG (1) | SG11201405129RA (https=) |
| WO (1) | WO2013128028A1 (https=) |
| ZA (1) | ZA201406078B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| EP3129371B1 (en) * | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6690543B2 (ja) | 2014-10-31 | 2020-04-28 | 宇部興産株式会社 | 置換ジヒドロピロロピラゾール化合物 |
| CN107530329B (zh) * | 2015-03-09 | 2021-10-08 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物 |
| CA2989519C (en) | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| CN107949563B (zh) * | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途 |
| WO2019032720A1 (en) | 2017-08-09 | 2019-02-14 | Sanford Burnham Prebys Medical Discovery Institute | APELIN RECEPTOR AGONISTS AND METHODS OF USE |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| IL276013B2 (en) * | 2018-01-17 | 2024-03-01 | Glaxosmithkline Ip Dev Ltd | Pi4kiiibeta inhibitors |
| EP3774809A1 (en) * | 2018-04-11 | 2021-02-17 | Qurient Co. Ltd. | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
| US12606561B2 (en) | 2018-04-11 | 2026-04-21 | Qurient Co., Ltd. | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors |
| EP3774810A1 (en) | 2018-04-11 | 2021-02-17 | Qurient Co. Ltd. | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
| US12022832B2 (en) | 2018-09-12 | 2024-07-02 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| US11517568B2 (en) | 2018-09-12 | 2022-12-06 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| CN113677346A (zh) | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US12304913B2 (en) | 2018-11-14 | 2025-05-20 | Ube Industries, Ltd. | Dihydropyrrolopyrazole derivative |
| CN110101703B (zh) * | 2019-05-06 | 2021-06-11 | 暨南大学 | Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用 |
| RU2713152C1 (ru) * | 2019-08-30 | 2020-02-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения хронической аллергической крапивницы на фоне описторхоза |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CN116964061A (zh) * | 2020-12-21 | 2023-10-27 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环嘧啶 |
| WO2022182918A1 (en) * | 2021-02-25 | 2022-09-01 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| US20240254138A1 (en) * | 2021-03-09 | 2024-08-01 | Janssen Pharmaceutica Nv | Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| AU2022318251A1 (en) | 2021-07-29 | 2024-01-25 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| US20250019382A1 (en) * | 2021-11-23 | 2025-01-16 | Origenis Gmbh | Novel inhibitors of cyclin-dependent kinases |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| WO2023175173A1 (en) * | 2022-03-18 | 2023-09-21 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077954A2 (en) * | 2004-02-11 | 2005-08-25 | Schering Corporation | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
| CN1922185A (zh) * | 2004-02-25 | 2007-02-28 | 先灵公司 | 作为激酶抑制剂的吡唑并三嗪类化合物 |
| WO2010103486A1 (fr) * | 2009-03-11 | 2010-09-16 | Centre National De La Recherche Scientifique | Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| HUP0200535A3 (en) * | 1999-02-01 | 2002-11-28 | Cv Therapeutics Inc Palo Alto | 2,6,9-trisubstituted purine derivatives inhibitors of cyclin dependent kinase 2 and ikappa-b-alpha and pharmaceutical compositions containing them |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
-
2012
- 2012-03-01 EP EP12157751.4A patent/EP2634190A1/en not_active Withdrawn
-
2013
- 2013-03-01 AU AU2013224848A patent/AU2013224848B2/en active Active
- 2013-03-01 US US14/381,146 patent/US9567345B2/en active Active
- 2013-03-01 RU RU2014139705A patent/RU2645347C2/ru active
- 2013-03-01 BR BR112014021189-2A patent/BR112014021189B1/pt active IP Right Grant
- 2013-03-01 CA CA2865946A patent/CA2865946C/en active Active
- 2013-03-01 JP JP2014559259A patent/JP6182549B2/ja active Active
- 2013-03-01 HU HUE13707008A patent/HUE029264T2/en unknown
- 2013-03-01 DK DK13707008.2T patent/DK2820020T3/en active
- 2013-03-01 WO PCT/EP2013/054224 patent/WO2013128028A1/en not_active Ceased
- 2013-03-01 ES ES13707008.2T patent/ES2583231T3/es active Active
- 2013-03-01 SG SG11201405129RA patent/SG11201405129RA/en unknown
- 2013-03-01 MX MX2014010494A patent/MX347359B/es active IP Right Grant
- 2013-03-01 CN CN201380011917.5A patent/CN104350054B/zh active Active
- 2013-03-01 KR KR1020147027812A patent/KR101821452B1/ko active Active
- 2013-03-01 EP EP13707008.2A patent/EP2820020B1/en active Active
-
2014
- 2014-08-19 ZA ZA2014/06078A patent/ZA201406078B/en unknown
- 2014-08-19 IL IL234183A patent/IL234183A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077954A2 (en) * | 2004-02-11 | 2005-08-25 | Schering Corporation | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors |
| CN1922185A (zh) * | 2004-02-25 | 2007-02-28 | 先灵公司 | 作为激酶抑制剂的吡唑并三嗪类化合物 |
| WO2010103486A1 (fr) * | 2009-03-11 | 2010-09-16 | Centre National De La Recherche Scientifique | Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique |
Non-Patent Citations (2)
| Title |
|---|
| Pyrazolo[1,5-a]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-Dependent Kinase Inhibitor (R)-Roscovitine Analogue;Florence Popowycz，等;《Journal of Medicinal Chemistry》;20090701;第52卷(第3期);第655-663页 * |
| Synthesis and antiproliferative evaluation of pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives;Florence Popowycz，等;《Bioorganic & Medicinal Chemistry》;20090310;第17卷(第9期);第3471-3478页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013128028A8 (en) | 2014-10-02 |
| JP2015511952A (ja) | 2015-04-23 |
| WO2013128028A1 (en) | 2013-09-06 |
| EP2820020A1 (en) | 2015-01-07 |
| ES2583231T3 (es) | 2016-09-19 |
| SG11201405129RA (en) | 2014-09-26 |
| CN104350054A (zh) | 2015-02-11 |
| EP2820020B1 (en) | 2016-04-06 |
| KR101821452B1 (ko) | 2018-01-23 |
| CA2865946A1 (en) | 2013-09-06 |
| MX2014010494A (es) | 2015-04-08 |
| AU2013224848A1 (en) | 2014-08-28 |
| RU2014139705A (ru) | 2016-04-20 |
| US20150018329A1 (en) | 2015-01-15 |
| MX347359B (es) | 2017-04-06 |
| KR20140131994A (ko) | 2014-11-14 |
| BR112014021189B1 (pt) | 2022-08-16 |
| US9567345B2 (en) | 2017-02-14 |
| HUE029264T2 (en) | 2017-02-28 |
| AU2013224848B2 (en) | 2017-06-29 |
| CA2865946C (en) | 2020-01-21 |
| RU2645347C2 (ru) | 2018-02-21 |
| JP6182549B2 (ja) | 2017-08-16 |
| ZA201406078B (en) | 2016-08-31 |
| EP2634190A1 (en) | 2013-09-04 |
| HK1206014A1 (en) | 2015-12-31 |
| DK2820020T3 (en) | 2016-07-04 |
| IL234183A (en) | 2016-11-30 |
| BR112014021189A2 (https=) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104350054B (zh) | 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 | |
| US9096608B2 (en) | Pharmaceutically active pyrazolo-triazine derivatives | |
| AU2023202086B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| CN103562184B (zh) | 药学活性的二取代的吡啶衍生物 | |
| RU2390522C2 (ru) | Гетероциклические соединения | |
| CN103582482B (zh) | 药学活性的二取代的三嗪衍生物 | |
| CN102933561A (zh) | 具有药学活性的二取代三嗪衍生物 | |
| US12240828B2 (en) | Heteroaromatic compounds as vanin inhibitors | |
| CN115989231B (zh) | 一种作为btk抑制剂的化合物及其制备方法与用途 | |
| CA2612008A1 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| HK1206014B (en) | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | |
| WO2020200154A1 (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
| HK1193813B (en) | Pharmaceutically active disubstituted pyridine derivatives | |
| HK1192470A (en) | Pharmaceutically active disubstituted triazine derivatives | |
| HK1192470B (en) | Pharmaceutically active disubstituted triazine derivatives | |
| HK1181771B (en) | Pharmaceutically active disubstituted triazine derivatives | |
| CN101146797A (zh) | 用于治疗炎性疾病的作为p38map-激酶抑制剂的4-′2-(环烷基氨基)嘧啶-4-yl！-3-(苯基)-咪唑啉-2-酮衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206014 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1206014 Country of ref document: HK |